Fusion Pharmaceuticals Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024053958 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $210.5M
YoY Change 0.32%
Cash & Equivalents $27.79M
Short-Term Investments $182.7M
Other Short-Term Assets $432.0K
YoY Change -66.69%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $6.214M
Total Short-Term Assets $220.9M
YoY Change 0.13%
LONG-TERM ASSETS
Property, Plant & Equipment $6.584M
YoY Change 28.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $72.59M
YoY Change 540.19%
Other Assets $652.0K
YoY Change -88.06%
Total Long-Term Assets $102.9M
YoY Change 124.04%
TOTAL ASSETS
Total Short-Term Assets $220.9M
Total Long-Term Assets $102.9M
Total Assets $323.8M
YoY Change 21.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.503M
YoY Change 31.46%
Accrued Expenses $17.87M
YoY Change 23.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $50.00M
YoY Change 42.86%
Total Short-Term Liabilities $20.76M
YoY Change 19.8%
LONG-TERM LIABILITIES
Long-Term Debt $49.69M
YoY Change 44.6%
Other Long-Term Liabilities $11.54M
YoY Change -17.76%
Total Long-Term Liabilities $49.69M
YoY Change 44.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.76M
Total Long-Term Liabilities $49.69M
Total Liabilities $81.98M
YoY Change 24.75%
SHAREHOLDERS EQUITY
Retained Earnings -$410.4M
YoY Change 34.03%
Common Stock $652.8M
YoY Change 28.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $241.8M
YoY Change
Total Liabilities & Shareholders Equity $323.8M
YoY Change 21.48%

Cashflow Statement

Concept 2024 Q2 2024 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001805890
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
CY2024Q1 fusn Type Of Revenues Extensible List
TypeOfRevenuesExtensibleList
us-gaap:CollaborativeArrangementMember
CY2023Q1 fusn Type Of Revenues Extensible List
TypeOfRevenuesExtensibleList
us-gaap:CollaborativeArrangementMember
CY2024Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2024Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2030-08-31
CY2019Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-02-28
CY2021Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2038-06-30
CY2022Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2030-08-31
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39344
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Fusion Pharmaceuticals Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
270 Longwood Rd., S.
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hamilton
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
ON
CY2024Q1 dei Entity Address Country
EntityAddressCountry
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
L8P 0A6
CY2024Q1 dei City Area Code
CityAreaCode
289
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
799-0891
CY2024Q1 dei Security12b Title
Security12bTitle
Common shares, no par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
FUSN
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85059965
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27790000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61456000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
7000
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
182735000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
172153000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9923000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9310000
CY2024Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
469000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
469000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
220917000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
243395000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6584000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5304000
CY2024Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4366000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3961000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
849000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
849000
CY2024Q1 us-gaap Long Term Investments
LongTermInvestments
72585000
CY2023Q4 us-gaap Long Term Investments
LongTermInvestments
13735000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17861000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18592000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
652000
CY2024Q1 us-gaap Assets
Assets
323814000
CY2023Q4 us-gaap Assets
Assets
285836000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2503000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1860000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13632000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9864000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
333000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
333000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4288000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4163000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
20756000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16220000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49686000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34775000
CY2024Q1 fusn Income Taxes Payable Noncurrent
IncomeTaxesPayableNoncurrent
301000
CY2023Q4 fusn Income Taxes Payable Noncurrent
IncomeTaxesPayableNoncurrent
301000
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
667000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
667000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10573000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11393000
CY2024Q1 us-gaap Liabilities
Liabilities
81983000
CY2023Q4 us-gaap Liabilities
Liabilities
63356000
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84865021
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84865021
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79700262
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79700262
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
652842000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
599002000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-582000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
237000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410429000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-376759000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
241831000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
222480000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
323814000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
285836000
CY2023Q1 us-gaap Revenues
Revenues
28000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21312000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15877000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14548000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9006000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
35860000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
24883000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-35860000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24855000
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
3508000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
1921000
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
1852000
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
1223000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
297000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-145000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1953000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
553000
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-33907000
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-24302000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-237000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33670000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24291000
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-819000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
384000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34489000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23907000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83775652
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83775652
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53775985
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53775985
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
222480000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
227000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
627000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4517000
CY2024Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-819000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33670000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
241831000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
162221000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3149000
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
384000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24291000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
200833000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-33670000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-24291000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4517000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3149000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
361000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
273000
CY2024Q1 fusn Non Cash Lease Expense
NonCashLeaseExpense
859000
CY2023Q1 fusn Non Cash Lease Expense
NonCashLeaseExpense
405000
CY2024Q1 fusn Non Cash Interest Expense
NonCashInterestExpense
223000
CY2023Q1 fusn Non Cash Interest Expense
NonCashInterestExpense
127000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1214000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1101000
CY2024Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-405000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-494000
CY2024Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
323000
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
613000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2663000
CY2024Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
652000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-177000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
445000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-704000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3658000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-35000
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
97000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-499000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-346000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27306000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25435000
CY2024Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
118607000
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
62422000
CY2024Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
49570000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
39117000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1334000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1223000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70371000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24528000
CY2024Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
14915000
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
60005000
CY2024Q1 fusn Proceeds From Issuance Of Common Shares From At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonSharesFromAtMarketOfferingNetOfIssuanceCosts
48469000
CY2023Q1 fusn Proceeds From Issuance Of Common Shares From At Market Offering Net Of Issuance Costs
ProceedsFromIssuanceOfCommonSharesFromAtMarketOfferingNetOfIssuanceCosts
3367000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3857000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
627000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64011000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59515000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33666000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9552000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62774000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45333000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29108000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54885000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
1629000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1096000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
12560000
CY2024Q1 fusn Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
308000
CY2023Q1 fusn Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
169000
CY2023Q1 fusn Common Share Issuance Costs Included In Accounts Payable And Accrued Expenses
CommonShareIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
145000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33700000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24300000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410400000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, valuations of share-based awards, valuation allowance of deferred tax assets, and revenue recognition. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-300000
CY2019Q4 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1500000
CY2024Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1000000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
29100000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
62800000
CY2024Q1 us-gaap Cash
Cash
27800000
CY2023Q4 us-gaap Cash
Cash
61500000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
1300000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
1300000
CY2023Q4 fusn Contract With Customer Assets Accounts Receivable Current
ContractWithCustomerAssetsAccountsReceivableCurrent
7000
CY2024Q1 fusn Contract With Customer Assets Accounts Receivable Current Deductions
ContractWithCustomerAssetsAccountsReceivableCurrentDeductions
-7000
CY2023Q4 fusn Contract With Customer Liability Deferred Revenue Current
ContractWithCustomerLiabilityDeferredRevenueCurrent
1000000
CY2024Q1 fusn Contract With Customer Liability Deferred Revenue Current
ContractWithCustomerLiabilityDeferredRevenueCurrent
1000000
CY2024Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
270613000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
191142000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
183099000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
182735000
CY2024Q1 fusn Available For Sale Securities Debt Maturities After One Through Three Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost
72803000
CY2024Q1 fusn Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
72585000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
255902000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
255320000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
171936000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
172153000
CY2023Q4 fusn Available For Sale Securities Debt Maturities After One Through Three Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsAmortizedCost
13715000
CY2023Q4 fusn Available For Sale Securities Debt Maturities After One Through Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughThreeYearsFairValue
13735000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
185651000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
185888000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
255902000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
28000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
610000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
218000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9923000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9310000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
255320000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
182735000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
72585000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
185651000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
368000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
131000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
185888000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
172153000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
13735000
CY2024Q1 fusn Prepaid External Research And Development Expenses
PrepaidExternalResearchAndDevelopmentExpenses
2452000
CY2023Q4 fusn Prepaid External Research And Development Expenses
PrepaidExternalResearchAndDevelopmentExpenses
2249000
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
477000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
981000
CY2024Q1 fusn Prepaid Software Subscriptions
PrepaidSoftwareSubscriptions
-348000
CY2023Q4 fusn Prepaid Software Subscriptions
PrepaidSoftwareSubscriptions
-397000
CY2024Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
1950000
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
2117000
CY2024Q1 us-gaap Interest Receivable
InterestReceivable
1343000
CY2023Q4 us-gaap Interest Receivable
InterestReceivable
822000
CY2024Q1 fusn Due From Collaboration Partner
DueFromCollaborationPartner
1163000
CY2023Q4 fusn Due From Collaboration Partner
DueFromCollaborationPartner
931000
CY2024Q1 fusn Canadian Harmonized Sales Tax Receivable
CanadianHarmonizedSalesTaxReceivable
-224000
CY2023Q4 fusn Canadian Harmonized Sales Tax Receivable
CanadianHarmonizedSalesTaxReceivable
-338000
CY2024Q1 fusn Refundable Deposits Due From Counterparties
RefundableDepositsDueFromCounterparties
1534000
CY2023Q4 fusn Refundable Deposits Due From Counterparties
RefundableDepositsDueFromCounterparties
1257000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
432000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2606000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4956000
CY2024Q1 fusn Accrued External Research And Development Services Current
AccruedExternalResearchAndDevelopmentServicesCurrent
4466000
CY2023Q4 fusn Accrued External Research And Development Services Current
AccruedExternalResearchAndDevelopmentServicesCurrent
3925000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6511000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
899000
CY2024Q1 fusn Other Accruals And Other Current Liabilities
OtherAccrualsAndOtherCurrentLiabilities
49000
CY2023Q4 fusn Other Accruals And Other Current Liabilities
OtherAccrualsAndOtherCurrentLiabilities
84000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13632000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9864000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
50000000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
35000000
CY2024Q1 fusn Accretion Of Final Fee
AccretionOfFinalFee
577000
CY2023Q1 fusn Accretion Of Final Fee
AccretionOfFinalFee
440000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
891000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
665000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49686000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34775000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
235402000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
15673408
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.33
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
15217000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
26087000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
8696000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
50000000
CY2024Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each common share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders.
CY2024Q1 us-gaap Dividends
Dividends
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0385
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.706
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.652
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14084895
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.99
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
61965000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1798100
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.17
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
56675
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.16
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
107379
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.21
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15718941
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.34
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
234973000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8212826
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.68
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
120236000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.05
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.31
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
43800
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.91
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1667300
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.44
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
4100
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
8.44
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1707000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.38
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4517000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3149000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
26700000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-33670000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-24291000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83775652
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83775652
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53775985
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53775985
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.4
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.4
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17459759
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14206636
CY2024Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In August 2018, the Company entered into an operating lease for office space in Hamilton, Ontario. This lease was amended in September 2020 (“New Lease Commencement Date”) and expires in August 2030 with a termination option upon twelve months written notice any time after the fifth anniversary of the New Lease Commencement Date. If the termination option is not exercised, the Company may exercise a renewal option to extend the term for an additional five-year period through August 2035. As the Company is not reasonably certain to extend the lease beyond the allowable termination date, the lease term was determined to end in August 2026 for the purposes of measuring this lease.
CY2024Q1 fusn Operating Lease Termination Notice Period
OperatingLeaseTerminationNoticePeriod
P12M
CY2024Q1 fusn Operating Lease Additional Lease Period
OperatingLeaseAdditionalLeasePeriod
P5Y
CY2024Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
false
CY2021Q1 fusn Allowance For Lease Improvements
AllowanceForLeaseImprovements
200000
CY2024Q1 fusn Lease Improvements And Expansions Description
LeaseImprovementsAndExpansionsDescription
The rental payments for the Expansion Premises commenced on January 1, 2022.
CY2024Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease end date for the Original Premises and the Expansion Premises is April 30, 2027, with no option to extend the lease term.
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
900000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1200000
CY2021Q2 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company’s rent for the manufacturing facility commenced in July 2023. The lease end date for the manufacturing facility is in June 2038. The lease has a five-year renewal option, which the Company is not reasonably certain to exercise and therefore was not included in the expected lease term.
CY2021Q2 fusn Operating Lease Additional Lease Period
OperatingLeaseAdditionalLeasePeriod
P5Y
CY2022Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease has a five-year renewal option upon twelve months written notice prior to the expiration of the original term
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
300000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1205000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
496000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
29000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
22000
CY2024Q1 us-gaap Lease Cost
LeaseCost
1234000
CY2023Q1 us-gaap Lease Cost
LeaseCost
518000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y2M12D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
973000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3485000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3367000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2400000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1322000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1290000
CY2024Q1 fusn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
12191000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24055000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9194000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
14861000
CY2024Q1 fusn Payment For Termination Of Operating Lease
PaymentForTerminationOfOperatingLease
500000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6584000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5304000

Files In Submission

Name View Source Status
0000950170-24-053958-index-headers.html Edgar Link pending
0000950170-24-053958-index.html Edgar Link pending
0000950170-24-053958.txt Edgar Link pending
0000950170-24-053958-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fusn-20240331.htm Edgar Link pending
fusn-20240331.xsd Edgar Link pending
fusn-ex31_1.htm Edgar Link pending
fusn-ex31_2.htm Edgar Link pending
fusn-ex32_1.htm Edgar Link pending
fusn-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
fusn-20240331_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending